Pan-Cancer分析和单细胞分析揭示了FAM110B是生存和免疫疗法的潜在目标
Pan-cancer analysis and single-cell analysis reveals FAM110B as a potential target for survival and immunotherapy
影响因子:4.00000
分区:生物学3区 / 生化与分子生物学3区
发表日期:2024
作者:
Yuwei Li, Xiaoxi Li, Bihua Wu, Shuangyan Su, Yunpeng Su, Le Guo
摘要
背景：FAM110B属于具有110个序列相似性（FAM110）的家族，位于中心体和有丝分裂纺锤体中。在早期研究中，FAM110B与肿瘤细胞生长有关。关于FAM110B在肿瘤微环境中的功能以及泛伴奏尚不清楚的FAM110B功能的不确定性。方法：为了评估正常和泛伴组织中FAM110b表达的变化，我们将TCGA和GTEX数据库组合在一起。 CBIOPORTAL数据库和GSCALITE平台用于检查FAM110B的基因组和甲基化改变的变化。 Cox回归，Kaplan-Meier和Sangerbox被用来检查FAM110B和Pan-Cancer的临床特征和预后。相关研究的目的是研究免疫相关基因，肿瘤突变负担，微卫星不稳定性，与免疫相关基因以及免疫学检查点和FAM110B表达中的关联。估计，史诗，Quantiseq和McPcounter方法用于计算FAM110B表达以及肿瘤免疫微环境之间的相互作用。通过单细胞数据库（Tisch和Cancersea）分析了FAM110B的免疫浸润和功能。最后，我们通过GDSC和CTRP数据库评估了FAM110B对小分子药物的敏感性。结果：FAM110B的转录和蛋白质表达在范围内均有很大差异，这对于某些肿瘤的预后具有预测价值。在肿瘤微环境中，包括大脑低年级胶质瘤（LGG），胃腺癌（Stad），胰腺腺癌（PAAD）等，FAM110B的表达水平与免疫细胞浸润，免疫检查点免疫调节基因，肿瘤突变伯氏症和微质量易变范围相关。结论：这项工作调查了FAM110B的实用性，以此作为预测泛滥的免疫疗法反应的标志，为癌症治疗提供了理论基础。
Abstract
Background: FAM110B belongs to the family that has a 110 sequence similarity (FAM110) and is located in the centrosome and mitotic spindle. FAM110B has been linked to tumor cell growth in earlier research. Uncertainty exists regarding FAM110B's function within the tumor microenvironment is unclear as well as pan-cancer. Methods: In order to assess the variation in FAM110B expression within normal and pan-cancer tissues, we combined the TCGA and GTEx databases. The cBioPortal database and the GSCALite platform were used to examine the variation in genome and methylation alteration of FAM110B. Cox regression, Kaplan-Meier, and SangerBox were employed to examine the clinical features and prognosis of FAM110B and pan-cancer. The purpose of the correlational research was to investigate the associations within immunerelated genes, tumor mutation burden, microsatellite instability, immune-related genes, and immunological checkpoints and FAM110B expression. ESTIMATE, EPIC, QUANTISEQ, and MCPCOUNTER methods were used to calculate the interaction among FAM110B expression as well as the tumor immune microenvironment. The immunoinfiltration and function of FAM110B were analyzed by single-cell databases (TISCH and CancerSEA). Finally, we evaluated the sensitivity of FAM110B to small-molecule medications through GDSC and CTRP databases. Results: The transcription and protein expression of FAM110B varies significantly throughout cancer types, and this has predictive value for the prognosis of some tumors; including brain lower grade glioma (LGG), stomach adenocarcinoma (STAD), pancreatic adenocarcinoma (PAAD), etc. In the tumor microenvironment, the expression level of FAM110B was associated with immune cell infiltration, immune checkpoint immune regulatory genes, tumor mutational burden, and microsatellite fragility to a certain extent. Conclusion: This work investigates the possibility of utility of FAM110B as a marker to forecast pan-cancer immunotherapy response, providing a theoretical basis for cancer therapy.